In this video interview, Dr. Hooman Noorchashm, surgeon and patient safety advocate, explains why he’s written a second letter to the FDA urging the agency to require pre-screening for SARS-CoV-2 viral proteins in order to reduce COVID vaccine injuries and deaths.
James Lyons-Weiler, Ph.D.
Robert F. Kennedy, Jr.
Dr. Hooman Noorchashm’s #ScreenB4Vaccine plan is coming into view by many as a potentially important way to protect the vast subset of Americans who have already been naturally infected with COVID-19 and are thus immune.
In the below video, Noorchashm, an accomplished surgeon and patient safety advocate, argues that at least a fraction of these millions of already infected Americans — especially the elderly, frail and those with serious cardiovascular comorbidities — are at risk of being harmed by a dangerous exaggerated immune response triggered by the COVID vaccine.
Additionally, Noorchashm says that by limiting vaccinations to those who are not already immune, the U.S. can not only protect people from being harmed by the vaccine, but can also get to herd immunity even faster by vaccinating only those who would truly benefit from the vaccine.
The question of whether people who have already been exposed to SARS-CoV-2 viral proteins, as is the case with those who have had COVID, should be offered SARS-CoV-2 vaccine is inextricably tied to the question of medical ethics: The vaccination of those who are already immune is seen by many — patients and physicians alike — as unethical because it is an unnecessary, all-risk, no-benefit, medical procedure.
In such cases, there are established medical grounds for grave concern. One concern is the possibility that some people who get vaccinated will experience disease enhancement, a condition that could cause them to develop more severe symptoms when exposed to the wild virus than if they hadn’t been vaccinated.
Pathogenic priming is another concern, now confirmed by researchers at Harvard Medical School, Boston General Hospital and elsewhere.
Noorchashm raises a third concern: that viral antigens may linger in antigen-presenting cells or elsewhere leading to multi-organ immunopathology in people who receive the COVID vaccines.
As The Defender previously reported, in January, Noorshashm wrote to the U.S. Food and Drug Administration (FDA) warning of the danger COVID vaccines pose to the recently convalescent or asymptomatic carriers of SARS-CoV-2, including the elderly and anyone with significant cardiovascular risk factors.
Last month, Noorchashm wrote a second letter to the FDA, in which he called for people to be pre-screened for risk before being vaccinated, so as to reduce serious illness and mortality attributed to COVID-19 and COVID-19 vaccines. In his letter, Noorchashm writes:
“It is my sincere hope that these gentlemen along with the other executives and risk managers at Pfizer will have the clarity and foresight to urgently act on my recommendation: to amend their vaccine warning label with FDA, so as to mitigate against the risk of potential harm to the recently or currently infected “class” of persons being considered for vaccination.”
If the FDA fails to act, local physician groups should publish white papers establishing their views to help establish bottom-up standards-of-care in their community.
In the interview on #UnbreakingScience, we discuss Noorchashm’s latest letter to the FDA and why he believes it’s urgent that more people be pre-screened for SARS-CoV-2 viral proteins before being vaccinated against COVID.
Watch a clip below from James Lyon-Weiler’s interview with Dr. Dr. Hooman Noorchashm. Click here to watch the entire interview.
VIEW VIDEO HERE: https://childrenshealthdefense.org/defender/screenb4vaccine-could-protect-covid-vaccine-injuries/
Thanks to: https://childrenshealthdefense.org